The Hematology Department at Skåne University Hospital in Lund has been granted an ethical permission to conduct a pilot study with the VibroSense Meter. The purpose of the study is to measure the degree of nerve damage in the treatment of cancer.
The study covers about 25 patients and will start in autumn 2017 and end in fall 2018. VibroSense Meter will be used in the study to examine the sensitivity of patients with bone marrow cancer, called myeloma. It is common for patients treated with cytostatics to suffer from complications in the form of neuropathy in the hands and feet. The study will investigate the impact of different doses of cytotoxic substances in terms of Chemotherapy-induced Peripheral Neuropathy, CIPN.
For VibroSense Dynamics, this is an important study as it opens up another area for the company’s method and instrument, the VibroSense Meter. Secondly, the instrument can be used in studies and at a later stage, even in the clinical care of patients treated with cytostatics.
– This is a very interesting study for VibroSense Dynamics. We know that nerve damage caused by chemo therapy is a major problem in the treatment of cancer today. There is a significant need to be able to measure and quantify the degree of nerve damage. In an extension, physicians may get a valuable tool for reducing the amount of permanent nerve damage after a cancer treatment with cytostatics, “says Ulf Rogers, Sales and Marketing Manager at VibroSense Dynamics AB.